BRCA2 and prostate cancer: The latter mutations, which were observed in five patients (that is, CRPC2-3, CRPC5, CSPC2, CSPC4), are likely somatic mutations and occurred in genes previously implicated in prostate cancer tumorigenesis, such as TP53, BRCA1, BRCA2, and MLL3 (see Additional file 1, Table S4).